ClinicalTrials.gov ID NCT04979052 Sponsor Radboud University Medical Center Study Overview – Brief Summary A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patients with candidemia. Detailed Description A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety [READ MORE]
ClinicalTrials.gov ID NCT06137950 Sponsor Mongolian National University of Medical Sciences Study Overview – Brief Summary Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millennium project in cooperation with WHO. [READ MORE]
The International Cytokines & Interferon Society (ICIS) thrives on the invaluable contributions of individuals who generously devote their time and expertise to the Society. As we look to the future, we invite you, our members, to consider stepping into leadership roles that will drive the field of cytokine and interferon research to new heights. [READ MORE]
The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. At BMS, I lead a translational research lab in Summit, NJ focused on immune regulation at mucosal sites. I create the translational research, precision medicine and biomarker plans for early-stage immunology assets approaching first-in-human and proof of [READ MORE]
Photo Credit: Burcu Elmas (pexels.com 10051526) The CD4 Versus CD8 T Cell Fate Decision: A Multiomics-Informed Perspective. PMID: 38271641 Steier Z, Kim EJY, Aylard DA, Robey EA. Annu Rev Immunol. 2024 Jun;42(1):235-258. doi: 10.1146/annurev-immunol-083122-040929. Epub 2024 Jun 14.PMID: 38271641 Free article. Review. The Immunobiology and Treatment of Food Allergy. PMID: 38360544 Barshow S, [READ MORE]
Join me in giving a warm welcome to our newest members who have joined since December! 👋 Thank you for joining our ICIS community. Prof. Beate Sodeik, Hannover Medical School – MHH, OE 5230, Hannover, Germany Jacob Kohlmeier, Ph.D., Emory University School of Medicine, Atlanta, Georgia, USA Chisang Hwang, Ph.D., [READ MORE]
The following perspective is by ICIS Member, Javier Mora, Ph.D., University of Costa Rica, Faculty of Microbiology. We welcome your comments and feedback, either to Prof. Mora (javierfrancisco.mora @ ucr.ac.cr) directly or to the ICIS Managing Director, Stephanie Flores (sflores @ cytokinesociety.org). Research in cytokines and immunology plays a pivotal [READ MORE]
The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. My lab in Australia works on understanding how humoral memory is formed, and how this goes awry in chronic infection. I’m excited to be able to learn and make new collaborations from joining the Cytokine Society, so [READ MORE]
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia ClinicalTrials.gov ID NCT05395507 Sponsor Institute of Hematology & Blood Diseases Hospital, China
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers ClinicalTrials.gov ID NCT03388632 Sponsor National Cancer Institute (NCI) Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party)
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
